ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 04 Jun 2024
Last Updated on 04 Jun 2024
A- A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
  • Latanoprost/timolol 0.005%/0.5% eye drops
in line with its registered indication for reducing intraocular pressure in patients with open-angle glaucoma and ocular hypertension, in view of acceptable price proposal from the manufacturer.

Funding status

Latanoprost/timolol 0.005%/0.5% eye drops is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication.

SDL subsidy does not apply to:
  • bimatoprost/timolol 0.03%/0.5% eye drops;
  • tafluprost/timolol 0.0015%/0.5% eye drops; and
  • travoprost/timolol 0.004%/0.05% eye drops
in view of unacceptable price proposals from the manufacturers.


Prostaglandin analogue with timolol fixed-dose combination eye drops for treatment of open-angle glaucoma or ocular hypertension (Published 4 Jun 24)